Petros Pharmaceuticals, Inc. (PTPI)
NASDAQ: PTPI · IEX Real-Time Price · USD
0.430
-0.003 (-0.72%)
At close: Jul 2, 2024, 4:00 PM
0.425
-0.005 (-1.12%)
After-hours: Jul 2, 2024, 7:17 PM EDT
Petros Pharmaceuticals Revenue
Petros Pharmaceuticals had revenue of $4.69M in the twelve months ending March 31, 2024, down -22.36% year-over-year. Revenue in the quarter ending March 31, 2024 was $1.39M, a -44.84% decrease year-over-year. In the year 2023, Petros Pharmaceuticals had annual revenue of $5.82M, a decrease of -2.83%.
Revenue (ttm)
$4.69M
Revenue Growth
-22.36%
P/S Ratio
0.64
Revenue / Employee
$223,487
Employees
21
Market Cap
3.01M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.82M | -169.67K | -2.83% |
Dec 31, 2022 | 5.99M | -1.82M | -23.29% |
Dec 31, 2021 | 7.81M | -1.75M | -18.29% |
Dec 31, 2020 | 9.56M | -6.02M | -38.63% |
Dec 31, 2019 | 15.58M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
INVO Bioscience | 4.25M |
Sintx Technologies | 2.78M |
Helius Medical Technologies | 668.00K |
60 Degrees Pharmaceuticals | 569.86K |
Aditxt | 506.44K |
Catheter Precision | 439.00K |
Sonnet BioTherapeutics Holdings | 92.73K |
PTPI News
- 11 days ago - NextTrip, Inc Receives Nasdaq Notification Regarding Late 10K Filing and Continued Listing Requirements - Accesswire
- 7 weeks ago - Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe - Accesswire
- 2 months ago - Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health - Accesswire
- 2 months ago - Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) - Accesswire
- 3 months ago - Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status - Accesswire
- 3 months ago - NextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program - Accesswire
- 3 months ago - Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider - Accesswire
- 4 months ago - Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider - Accesswire